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Background: Epidemic viral diseases have become more prevalent.. Among the various strategies to prevent such
epidemics, vaccination is the most cost-effective. However, populations that are immunized are typically already
exposed to multiple previous vaccinations or natural infections. Studies from this and other laboratories have
revealed that pre-existing dengue antibodies can either inhibit or enhance subsequent dengue infection depending on
the pre-existing antibody levels. While cross-reactive antibody is potentially pathogenic in dengue, how it impacts
immune response to vaccination is unclear. Aggregated at the site of vaccination and the respective draining lymph
nodes are antigen-presenting and immune regulatory cells that express Fc receptors and play pivotal roles in
determining the magnitude and polarity of the immune response. Vaccine uptake by these antigen-presenting
cells may thus be either inhibited or enhanced when vaccines are opsonized with cross-reactive antibodies.
Design: In view of the limited knowledge on how cross-reactive antibodies affect vaccination outcome, we
propose a study that exploits the known cross reactivity between Japanese encephalitis (JE) virus antibody and
yellow fever (YF) vaccine. We hypothesize that cross-reactive antibodies impact antibody response to YF at the
point vaccination in a concentration-dependent manner by altering both vaccine uptake and the innate immune
response by antigen presenting cells. We will structure an open-label clinical trial on sequential vaccination with
JE and YF vaccines, with different time intervals between vaccinations. This would test immune response to YF
vaccination in subjects with different titer of cross-reactive JE vaccine-derived antibodies. The clinical materials
obtained in the trial will drive basic laboratory investigations directed at elucidating how heterologous antibody
affect vaccination at the molecular level. YF neutralizing antibody titer will be measured using plaque reduction
neutralization test against the vaccine strain YF17D. Innate immune response will be characterized genetically
using either microarray or digital PCR (or both). The innate immune response will also be characterized at the
protein and metabolite level using Luminex bead technology and lipidomic/metabolomic approaches.
Discussion: This proposed study represents one of the first to examine the role of cross-reactive antibodies in
modulating immune responses to vaccines, the findings of which may re-shape vaccination strategy.
Trial registration: Clinical Trials.gov registration number: NCT01943305 (3 September 2013).
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The increasing prevalence of viral epidemics in recent
decades threatens both human health and global econ-
omies. Among the countermeasures, vaccination re-
mains the single most cost-effective method of disease
prevention. One of the most popular forms of vaccines
is the live attenuated vaccine (LAV). LAV is a weakened
virus that is able to mimic natural infection and present
antigens in native conformation to immune cells, often
resulting in superior protection compared to other
forms of vaccines. However, populations that are im-
munized are typically already exposed to multiple pre-
vious vaccinations or natural infections against a range
of viruses. Since some of these viruses are evolutionar-
ily related and share antigenic epitopes with the LAV,
there is high likelihood of cross-reactivity between
LAV and pre-existing antibodies evoked against previ-
ous vaccination or infection. Although the impact of
these cross-reacting antibodies has largely been over-
looked, there is growing evidence that its impact can
be highly significant but widely varied [1-3]. Thus,
cross-reactive antibodies could, in some cases, boost
the efficacy of vaccines while in others render them
ineffective.
Studies from this and other laboratories have revealed
that pre-existing antibodies against certain dengue virus
(DENV) serotypes can enhance subsequent infection
with a heterologous serotype by promoting viral entry
and infection into Fc receptor-expressing cells [4-7].
While the presence of cross-reactive antibodies is poten-
tially detrimental in dengue [5,8-11], it is unclear how
cross-reactive antibodies may impact the efficacy of LAV
or other viral vector-based vaccines. Some of the critical
sites in the body where cross-reactive antibodies could
impact vaccination efficacy are at the site of vaccination
[12,13] and in the secondary lymph node draining the
vaccination site, where the innate and adaptive immune
responses are initiated, respectively [14,15]. Aggregated
at these sites are dendritic cells, monocytes, macro-
phages, and mast cells, which are either antigen present-
ing or immune regulatory cells that play pivotal roles in
determining the magnitude and polarity of the immune
response. As all of these cell types express Fc receptor,
cross-reactive antibodies can potentially and markedly
alter the nature of the initial interactions of vaccine an-
tigens with these immune surveillance and regulatory
cells and, by extension, the resulting immune response
[16]. It is conceivable that cross-reactive antibodies
may directly bind vaccine antigen and enhance Fc re-
ceptor uptake by antigen presenting cells resulting in
an enhanced and beneficial immune response. Alterna-
tively, these antibodies may aggregate vaccines to co-
ligate inhibitory Fc receptors, a mechanism that we
recently demonstrated [17], that reduces both entryinto these cells and hence vaccination efficacy. This
capacity of pre-existing antibodies to interfere with effi-
cacy of vaccines may explain why the use of adenovirus
and reovirus to deliver antigens has encountered very
mixed results [2,3,18-21].
Objectives and hypotheses
In view of the limited information available on the po-
tentially critical role heterologous antibodies have in
modulating the efficacy of LAVs, we propose here a
study that takes advantage of the known cross-reactivity
between antibodies to Japanese encephalitis (JE) virus
and yellow fever (YF) vaccine. We will structure human
and animal studies that inform on whether heterologous
antibody affects vaccination efficacy and how this is me-
diated molecularly. Our long-term goal is to maximize
the cost-effectiveness of vaccination by developing a per-
sonalized approach to vaccination where the dose of
vaccine is tailored to the background heterologous anti-
body titer of the vaccinee.
We hypothesize that cross-reactive antibodies impact
antibody response to YF at the point vaccination in a
concentration-dependent manner by altering both vaccine
uptake and the innate immune response by antigen-
presenting cells.
Primary objectives:
1. The primary objective of this clinical study is to
examine the role of cross-reactive antibodies in
modulating immune responses to vaccines.
a. Hypothesis: antibody response to YF vaccination is
influenced by the heterologous antibody titer at the
point of YF vaccination.
b. Hypothesis: heterologous antibody to YF affects the
magnitude of vaccine uptake through the Fc
receptors and alters the quality and magnitude of
the innate immune response following YF
vaccination, which has been previously shown to be
predictive of the immune response to YF vaccination.
c. Hypothesis: heterologous antibody titer affects the
response of Fc receptor-expressing antigen presenting
or immune regulatory cells to YF vaccination.
Secondary objectives:
1. To determine neutralizing antibody response to YF
vaccination in human volunteers at different time
intervals following a prior JE vaccination.
2. To characterize the innate immune response to YF
vaccination at different time intervals after a prior JE
vaccination.
3. To elucidate the dendritic cell, mast cell, monocyte
and macrophage response to YF vaccination in the
presence of heterologous JE antibodies in humans.
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1. To examine how heterologous antibody titer
influences the antibody response to vaccination.
While an obvious approach is to enroll participants
with varying titers of pre-existing antibodies, such as
dengue antibodies, that cross-react with YF vaccine
this would require a large population size to account
for qualitative and quantitative differences. To
overcome this we will take advantage of the natural
reduction in cross-reactive antibodies with increasing
amount of time from a prior JE vaccination.
2. To maximize the cost-effectiveness of vaccination by
developing a personalized approach to vaccination
where the dose of vaccine is tailored to the
background heterologous antibody titer of the vaccine.Methods/design
Trial approval and conduct
The trial is approved by the Singhealth centralised
Institutional Review Board (ID: 2013/385/E) and is reg-
istered on the clinicaltrials.gov registration number:
NCT01943305. The trial sponsor is the Singapore
General Hospital, Singapore, in collaboration with
Duke-NUS Graduate Medical School, Singapore. The
trial is funded by the Biomedical Research Council,
Singapore (BMRC reference 13/1/96/19/689) and will
be carried out in accordance with the principles of the
Singapore Good Clinical Practice guidelines and in
compliance with the Helsinki Declaration. Informed
consent is obtained for all patients before enrolment.Study design
The study design is shown in Table 1. Healthy volunteers
meeting all inclusion criteria will be enrolled and re-
cruited into the study at the Singhealth Investigational
Medicine Unit (IMU).
A total of 100 healthy adults, pre-screened to be nega-
tive for anti-dengue antibodies, will be enrolled upon
written informed consent; 75 subjects in the test arm
will receive two doses of inactivated JE vaccine (Ixiaro,
Novartis (Singapore) Pte Ltd, Pharmaceutical Division
20 Pasir Panjang Road #10-25/28 Mapletree BusinessTable 1 Study design
Groups Vaccination schedule
1st vaccination (month 1) 2nd vaccination (mon
Group 1 JE vaccination JE vaccination
Group 2 JE vaccination JE vaccination
Group 3 JE vaccination JE vaccination
Group 4 Yellow fever vaccination No vaccination
JE, Japanese encephalitis.City Singapore 117439), while 25 subjects in the control
arm will receive no JE vaccination.
Subjects in the test arm will be sub-divided into three
groups who receive YF17D (Stamaril, SANOFI PAS-
TEUR SA 2, avenue Pont Pasteur F-69007 Lyon France):
group 1, YF vaccination 1 month post-JE vaccination;
group 2, YF vaccination 4 months post-JE vaccination;
group 3, YF vaccination 9 months post-JE vaccination.
Subjects in the control arm (group 4) will receive YF
vaccination at month 1.
Blood sampling in relation to YF17D vaccination will
take place: 1) pre-dose; 2) 1 day post-dose; 3) 3 days
post-dose (+1 day); 4) 1 week post-dose (±2 days); 5)
1 month post-dose (±5 days); and 6) 6 months post-dose
(±14 days).
Selection and withdrawal of patients
Inclusion criteria
1. Healthy male or female adults, 21 to 50 years of age
at the time of screening.
2. Negative for anti-dengue antibodies by enzyme-linked
immunosorbent assay (ELISA).
3. Subjects who are willing to comply with the
requirements of the study protocol and scheduled
visits (for example, completion of the subject diary,
return for follow-up visits) and who are willing to
make themselves available for the duration of the
study with access to a consistent means of telephone
contact, which may be either at home or at the
workplace, and be either a land line, or mobile, but
not a pay phone or other multiple-user device (that is,
a common-use phone serving multiple rooms or
apartments).
4. Subjects who give written informed consent approved
by the Ethical Review Board governing the site.
5. Satisfactory baseline medical assessment as assessed
by physical examination and a stable health status.
The laboratory values must be within the normal
range of the assessing site or show abnormalities
that are deemed not clinically significant as judged
by the investigator. A stable health status is defined
as the absence of a health event satisfying the
definition of a serious adverse event.th 2) 3rd vaccination
Yellow fever vaccination 1 month after second JE vaccine
Yellow fever vaccination 4 months after second JE vaccine
Yellow fever vaccination 9 months after second JE vaccine
No vaccination
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7. Females of non-child bearing potential due to surgical
sterilization (hysterectomy or bilateral oophorectomy
or tubal ligation) or menopause.
8. Female subjects of childbearing potential may be
enrolled in the study
a. if they have a negative urine pregnancy test on the
day of screening and negative urine dipstick
pregnancy tests at the days of the vaccinations
b. if they use adequate, reliable contraception or
abstain from sexual intercourse during the entire
study for 1 year.Exclusion criteria
1. Presence of acute infection in the preceding 7 days
or presence of a temperature ≥38.0 °C (oral
temperature assessment), or acute symptoms greater
than “mild” severity on the scheduled date of first
vaccination.
2. History of severe drug and/or food allergies and/or
known allergies to the trial product or its
components.
3. Any condition that, in the opinion of the
investigator, would complicate or compromise the
study or wellbeing of the subject.
4. Woman who are pregnant or breast feeding.
5. History or presence of cardiovascular, respiratory,
hepatic, renal, gastrointestinal, neuropsychiatric, or
immunosuppressive disorders that would be a risk
factor when administering the investigational product.
6. History of thymus gland disease.
7. Diagnosed with cancer or receiving treatment for
cancer within the 3 years prior to the screening.
8. Evidence of clinically significant anemia and other
any significant active hematological disease, or
having donated >450 mL blood within the past
3 months.
9. Evidence of substance abuse, or previous substance
abuse.
10.Participation in a study involving administration of
an investigational compound within the past
4 months, or planned participation during the
duration of this study.
11.Administration of any licensed vaccine, such as
MMR and/or chickenpox immunization within
30 days before the first study vaccine dose.Figure 1 Dosing regimen. DENV, dengue virus; JE, Japanese
encephalitis; YF, yellow fever.Premature withdrawal of patients from study
Participants are free to withdraw consent and discon-
tinue participation at any time without penalty and are
not obliged to give a reason. Subjects may be with-
drawn/removed, if necessary, to protect their health orthe integrity of the study. The investigator also has the
right to withdraw participants from the study in the
event of inter-current illness, adverse events, treatment
failures, protocol violations, administrative, or other rea-
sons. When a subject withdraws from the study, all
safety data normally required at the completion of the
study will be obtained, where possible. All details avail-
able will be reported and recorded for any subject that
withdraws or is removed from the study.
The Principal Investigator and/or the Sponsor of this
study may stop a subject’s participation in the study at
any time for one or more of the following reasons:
 Failure to follow the instructions of the Principal
Investigator and/or study staff.
 The Principal Investigator decides that continuing
participation could be harmful.
 Treatment is needed that is not allowed in the study.
 The study is cancelled.
 Other administrative reasons.
 Unanticipated circumstances.
Dosing regimen
The dosing regimen is shown in Figure 1.
Methods and assessments
Subjects will be recruited via the Singhealth IMU healthy
volunteer database. Eligible subjects will be approached
and invited for participation. The participants will be
given the participant information sheet and allowed to
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gator or a Co-investigator will take informed consent.
Participants meeting all inclusion criteria and no exclu-
sion criteria and who agree to participate will be en-
rolled and randomized at the IMU.
Visit 1 – screening for all groups
Screening procedures will commence once a subject has
given informed consent. A physical examination and
blood samples will be taken for baseline assessments:
dengue immunoglobulin G specific for previous dengue
infection, and hematology for full blood count and clin-
ical chemistry (liver and renal panel). Urine will be
collected for a pregnancy test (for female subjects of
child-bearing potential only).
The study screening procedure is for all subjects, re-
gardless of their randomized group:
 Informed consent
 Physical examination
 Urine pregnancy test if applicable
 Safety bloods which include:




Subjects must receive the first dose of vaccination
within 21 days of the screening visit.
Procedures for groups 1, 2 and 3
The following procedures for subjects randomized to
groups 1, 2 and 3 are conducted at the following visits.
Visit 2 – dose 1 (Japanese encephalitis)
 Pre-dose vital signs
 Urine pregnancy test if applicable
 JE vaccination
 1 hour post-dose physical examination
 1 hour post-dose vital signs
Visit 3 – dose 2 (Japanese encephalitis)
This visit will occur 1 month after the first JE
vaccination.
 Pre-dose vital signs
 JE vaccination
 1 hour post-dose physical examination
 1 hour post-dose vital signs
Visit 4 – dose 3 (yellow fever)
This visit will occur 1 month after the second JE vaccin-
ation for subjects randomized to group 1, 4 months afterthe second JE vaccination for subjects randomized to
group 2, or 9 months after the second JE vaccination for
subjects randomized to group 3.
 Pre-dose vital signs
 Pre-dose research blood for YF antibody immune
response and RNA
 YF vaccination
 1 hour post-dose vital signs
 1 hour post-dose physical examination
Visit 5 – 1 day after yellow fever vaccination
 Vital signs
 Physical examination
 Research blood for YF antibody immune response
and RNA
 Assessment of clinical symptoms
Visit 6 – 3 days (+1 day) after yellow fever vaccination
 Vital signs
 Physical examination
 Research blood for YF antibody immune response
and RNA
 Assessment of clinical symptoms
Visit 7 – 1 week (±2 days) after yellow fever vaccination
 Vital signs
 Physical examination
 Research blood for YF antibody immune response
 Assessment of clinical symptoms
Visit 8 – 15 days (+2 days) after yellow fever vaccination
 Vital signs
 Physical examination
 Assessment of clinical symptoms
 Review subject diary
 Review adverse events and concomitant medications
Visit 9 – 1 month (±5 days) after yellow fever vaccination
 Vital signs
 Physical examination
 Research blood for YF antibody immune response




 Research blood for YF antibody immune response
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The following procedures for subjects randomized to
group 4 are conducted at these visits.
Visit 2 – Dose 1 (yellow fever)
 Pre-dose vital signs
 Urine pregnancy test if applicable
 Pre-dose research blood for YF antibody immune
response and RNA
 YF vaccination
 1 hour post-dose vital signs
 1 hour post-dose physical examination
Visit 3 – 1 day after yellow fever vaccination
 Vital signs
 Physical examination
 Research blood for YF antibody immune response
and RNA
 Assessment of clinical symptoms
Visit 4 – 3 days (+1 day) after yellow fever vaccination
 Vital signs
 Physical examination
 Research blood for YF antibody immune response
and RNA
 Assessment of clinical symptoms
Visit 5 – 1 week (±2 days) after yellow fever vaccination
 Vital signs
 Physical examination
 Research blood for YF antibody immune response
 Assessment of clinical symptoms
Visit 6 – 15 days (+2 days) after yellow fever vaccination
 Vital signs
 Physical examination
 Assessment of clinical symptoms
 Review subject diary
 Review adverse events and concomitant medications
Visit 7 – 1 month (±5 days) after yellow fever vaccination
 Vital signs
 Physical examination
 Research blood for YF antibody immune response
Visit 8 – 6 months (±14 days) after yellow fever vaccination
 Vital signs Physical examination
 Research blood for YF antibody immune response
Further assessments
During each study visit, subjects will document all symp-
toms they may experience after the vaccination with YF
vaccine. These assessments include local symptoms as
well as systemic symptoms. Investigators will check on
the presence of fever, nausea, vomiting and myalgia at
each point at day 1, day 3, week 1 and day 15. Patients
will be monitored again at month 1 and month 6. The
patient and their diary will be assessed and reviewed by
the investigators to ensure that there are no other symp-
toms experienced by the subjects. Subjects will be
trained to watch out for important clinical signs and
symptoms and any unusual manifestations such as high
fever, unusual behavior, fits, yellowing of skin and eyes,
or any signs and symptoms of a serious allergic reaction
such as difficulty breathing, hoarseness or wheezing,
hives, paleness, weakness, a fast heart beat or dizziness.
They will be educated to inform the study site personnel
and the Principal Investigator should any of them de-
velop any of these features.
YF neutralizing antibody titer will be measured using a
plaque reduction neutralization test against the vaccine
strain YF17D. Innate immune response will be charac-
terized genetically using either microarray or digital PCR
(or both). The innate immune response will also be
characterized at the protein and metabolite level using
Luminex bead technology and lipidomic/metabolomic
approaches.
Schematic diagrams of the study assessments are show
in Tables 2, 3, 4 and 5.
Sample size calculation and statistical analysis
The main analysis will be comparisons between each of
the JE groups and the no JE group. To allow for the risk
of inflated type 1 error rate, a Bonferroni-type adjust-
ment will be used. A sample size of 21 per group gives
80% power (5%/3 = 1.7% two-sided type 1 error) to de-
tect a difference of 1 unit of log(2)-transformed antibody
titer between two groups, assuming the standard devi-
ation is 1 on the log(2) scale. We anticipate a drop-out
rate of approximately 20%. However, given the long dur-
ation between JE and YF vaccination in group 3 of the
JE vaccination arm a higher loss to follow-up rate could
occur in this group. Given that group 2 in the JE vaccin-
ation arm serves as an intermediate while the largest dif-
ference in YF antibody titers is hypothesized to be in
groups 1 and 3 in the JE vaccination arm, we weighted
each arm differently. Consequently, n = 25 in the YF con-
trol arm, n = 25 for the group that receives YF vaccination
1 month after JE vaccination, n = 22 for the group that re-
ceives YF vaccination 4 months after JE vaccination, and
Table 2 Study schema for study arms 1, 2 and 3
Visit 1 screening
(-21 to -1 days)
Visit 2 - first vaccination
(day 0)
Visit 3 - second vaccination
(+2 weeks from first vaccination)*
Visit 4 - third vaccination
(+2 weeks from second vaccination)*
Pre-vaccination 1 hour post-vaccination Pre-vaccination 1 hour post-vaccination Pre-vaccination 1 hour post-vaccination
Inform consent ×
Medical history and demographics ×
Physical examination × x x x x ×
Vital signsa × × × × × × ×
Hematology labsb ×
Chemistry labs (liver, renal panelc) ×
Dengue immunoglobulinGd ×
Urine pregnancy teste × ×
Adverse eventsf × × × ×
Concomitant medications × × × ×
Blood sampling in relation to YF17D
vaccination
×g
*Window period: for second vaccination is +2 weeks (vaccination cannot be done earlier); for third vaccination (group 1, 2, 3) is +2 weeks (vaccination cannot be done earlier). aVital signs include temperature (oral and
tympanic allowed), blood pressure, pulse rate, and respiratory rate. bHematology labs include hemoglobin, red blood cell, white blood cell, hematocrit, platelet count, neutrophil, lymphocyte, monocyte, eosinophil,
basophil. cLiver panel includes total protein, albumin, total bilirubin, alkaline phosphatase, ALT alanine transaminase, AST aspartate transaminase, gamma-glutamyl transpeptidase. Renal panel includes urea, sodium,
potassium, chloride, bicarbonate, creatinine. dDengue immunoglobulin G will be tested by enzyme-linked immunosorbent assay. eFor females only. fClinical Trial Certificate Adverse Events version 4.0 will be used for









Table 3 Blood sampling schedule for study arms 1, 2, 3
Visit 4 Visit 5 - 1 day
after
Visit 6 - 3 days
after (+1 day)
Visit 7 - 1 week
after (±2 days)
Visit 8 - 15 days
after (+2 days)
Visit 9 - 1 month
after (±5 days)
Visit 10 - 6 months
after (±14 days)Pre-vaccination
(any time before dosing)
Post-vaccination
(1 hour)
Physical examination × × × × x × ×
Vital signsa × × × × × x × ×
Assessment for clinical symptoms
(local and general symptoms)
× × × × x
Blood sampling in relation to
YF17D vaccination
× × × × × ×
Adverse eventsb × × × × x × ×
Concomitant medications × × × × x × ×









Table 4 Schedule in relation to YF17D vaccination
Visit 4 Visit 5 - 1 day
after
Visit 6 - 3 days
after (±1 day)
Visit 7 - 1 week
after (±2 days)
Visit 8 - 1 month
after (±5 days)
Visit 9 - 1 year
after (±7 days)Pre-vaccination
(any time before dosing)
Post-vaccination
(1 hour)
Physical examination × × × × × ×
Vital signsa × × × × × × ×
Assessment for clinical symptoms
(local and general symptoms)
× × × × ×
Blood sampling in relation to
YF17D vaccination
× × × × × ×
Adverse eventsb × × × × × ×
Concomitant medications × × × × × ×









Table 5 Study schema for study group 4
Visit 1 – screening
(-21 to -1 days)
Visit 2 - first vaccination
(day 0)
Visit 3 - 1 day
after
Visit 4 - 3 days
after (+1 day)
Visit 5 - 1 week
after (±2 days)
Visit 6 - 15 days
after (+2 days)
Visit 7 - 1 month
after (±5 days)








Physical examination × × × × × x × ×
Vital signsa × × × × × × x × ×
Haematology labsb ×
Chemistry labs (liver, renal
panelc)
×
Dengue immunoglobulin Gd ×
Urine pregnancy teste × ×
Adverse eventsf × × × x
Concomitant medications × × × x
Blood sampling in relation to
YF17D vaccination
×g × × × × ×
Assessment for clinical symptoms
(local and general symptoms)
× × × × x
aVital signs include temperature (oral and tympanic allowed), blood pressure, pulse rate, and respiratory rate. bHematology labs include hemoglobin, red blood cell, white blood cell, hematocrit, platelet count,
neutrophil, lymphocyte, monocyte, eosinophil, basophil. cLiver panel includes total protein, albumin, total bilirubin, alkaline phosphatase, ALT alanine transaminase, AST aspartate transaminase, gamma-glutamyl transpeptidase.
Renal panel includes urea, sodium, potassium, chloride, bicarbonate, creatinine. dDengue immunoglobulin G will be tested by enzyme-linked immunosorbent assay. eFor females only. fClinical Trial Certificate Adverse Events
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after JE vaccination. The total number of participants is
therefore 100.
Randomization
To reduce potential bias in this open-label trial, subjects
will be randomized to the four treatment arms (groups
1, 2, 3 and 4); 100 sealed envelopes, each containing a
study arm, will be randomly picked by a non-study team
member (akin to drawing lots).
Data management
Direct data capture of demographic and clinical data will
be conducted using computer notebooks. The data will
be kept confidential in password-protected computers
accessible only by selected research staff. Identifiers will
be kept in a separate file in another office and every
effort will be made to protect the privacy of the partici-
pants. The data to be analyzed will contain only de-




An adverse event (AE) is defined as any untoward med-
ical occurrence in a subject administered a medicinal
product, which does not necessarily have a causal rela-
tionship with this treatment.
A serious adverse event (SAE) is defined as any untoward
medical occurrence that at any dose is life-threatening,
requires inpatient hospitalization or prolongation of exist-
ing hospitalization, results in persistent or significant dis-
ability/incapacity or is a congenital anomaly/birth defect.
For AEs, event terminology, the date and time of event
start and end, severity, relatedness, impact to the con-
tinuation of the study, and final outcome of the event
will be recorded on the case report form from day 0 to
the last study visit until the event has been resolved. For
a SAE, in addition to the above, an event summary, the
criteria used to categorize the event as an SAE, and a list
of all tests and treatments given for the event will be
documented.
Serious adverse event reporting
SAEs require expedited reporting. SAEs, whether or not
they are thought to be related to the investigational
drug, must be reported to the study monitor within
24 hours. Within that time, a completed SAE worksheet
and other available supporting documentation must be
forwarded to the study monitor by facsimile to JGL. All
patients with SAEs will be followed for outcome.
For SAEs that are related and unexpected resulting in
death or life-threatening events, an initial report must be
made to the Singhealth Institutional Review Board andthe Clinical Trials Branch of the Health Sciences Au-
thority within 7 calendar days of the event. For SAEs
that are related and unexpected resulting in non-fatal or
non-life threatening events, notification must occur
within 15 calendar days of the event. Refer to the Health
Science Authority’s Guidance “Safety Reporting Require-
ments for Clinical Trial Drugs” for further details of
reporting requirements.
Study monitoring
The study may be evaluated by government inspectors/
regulatory authorities who must be allowed access to
electronic case report forms, source documents, and
other study files. The inspectors will review case report
forms and compare them with source documents to ver-
ify accurate and complete collection of data and confirm
that the study is being conducted according to the
protocol, Singapore Good Clinical Practices and all ap-
plicable regulations.
Discussion
As far as we are aware, this is the first proof-of-concept
trial assessing the role of cross-reactive neutralizing anti-
body in subsequent vaccinations. If results from this
study suggest the immune response to vaccination is
modulated by pre-existing cross-reactive neutralizing
antibodies, this will potentially re-shape vaccination
strategy.
Trial status
The trial has been granted a Clinical Trial Certificate 707
by the Health Sciences Authority (certificate number:
CTC 1300291). The trial is currently still actively recruit-
ing and is anticipated to be completed by June 2015.
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